HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy
|
|
- Gyles Garrison
- 5 years ago
- Views:
Transcription
1 HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy Shigeya Kyoda 1, Satoki Kinoshita 2, Hiroshi Takeyama 1, Ken Uchida 2 and Toshiaki Morikawa 2 1 Department of Surgery, Jikei University Daisan Hospital, Komae and 2 Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan Received November 5, 2007; accepted September 3, 2008; published online October 4, 2008 Jpn J Clin Oncol 2008;38(11) doi: /jjco/hyn103 Objective: The overexpression of HER-2 protein has generally been considered to be consistent in primary and metastatic tumor tissues. We evaluated HER-2 protein overexpression levels in 31 autopsied cases. Methods: Hematoxylin eosin staining and immunohistological staining Hercep Test II TM were performed on the primary tumors and the lung, liver, brain and bone metastatic tumors. Results: Nine (29%) of the 31 primary tumors were HER-2 score 3þ and HER-2 score 3þ cases were significantly more frequent in carcinomas of nuclear Grade 3 than in those of Grade 1 or 2. In these 31 patients, the HER-2 status in the primary tumors was consistent with the metastatic foci of the lung, liver, brain and bone in 96% (25 of 26), 91% (21 of 23), 100% (12 of 12) and 85% (11 of 13), respectively. With regard to the nine patients with HER-2 score 3þ primary tumors, the HER-2 status in the primary tumors was consistent with the metastatic foci of the lung, liver, brain and bone in 87% (seven of eight), 78% (seven of nine), 100% (only one) and 33% (one of three), respectively. In 11 (92%) of the 12 patients with brain metastasis, the HER-2 was not overexpressed. Conclusions: Even in the far-advanced stages of autopsy, HER-2 status of the primary tumors appeared to be maintained especially in the foci of the lung, liver and brain metastases. As there was a high degree of agreement in HER-2 status between the primary tumors and the metastatic foci to the lung, liver and brain, it is considered to be reasonable to treat patients with such metastatic foci based on the HER-2 status of the primary tumors. Key words: breast cancer nuclear grade HER-2 protein overexpression autopsied patients INTRODUCTION Since Bloom and Richardson (1) reported the degree of histological malignancy in breast cancer, it has been widely accepted as a prognostic factor and used as one of the determinants for the selection of postoperative adjuvant therapies. At the 9th St Gallen Expert Consensus Meeting in 2005, the overexpression of HER-2/neu oncogene product (HER-2 protein) was added to the breast cancer risk categories (2). The overexpression of HER-2 protein has generally been considered to be consistent in primary and metastatic tumor tissues (3,4). However, only a few studies have HER-2 protein overexpression levels between primary and metastatic breast cancer tissues been compared (5,6) and reports on autopsied patients that would allow searching of systemic For reprints and all correspondence: Shigeya Kyoda, Department of Surgery, Jikei University Daisan Hospital, Izumi-honchou, Komae, Tokyo , Japan. vez06074@nifty.ne.jp metastatic foci are hardly available (7). In this study, we evaluated the relationship between the HER-2 score and nuclear grade of primary breast cancers and the overexpression levels of HER-2 protein between primary and metastatic breast cancer tissues. PATIENTS AND METHODS Of 89 autopsies performed on cases with breast cancer at our hospital between January 1980 and December 2001, 31 for whom death from breast cancer was histopathologically confirmed and the paraffin blocks of both primary tumors and metastatic tumors were obtained at the time of autopsy were included in this study. All were females aged (median 55 years) at the time of first presentation to our hospital. When surgical therapy was performed to the primary breast cancer, clinical stages of the disease were I in # The Author (2008). Published by Oxford University Press. All rights reserved.
2 744 HER-2 overexpression metastatic breast cancer Figure 1. (a) Microscopic findings of the primary tumor, HER-2 score 3þ, (b) site of brain metastasis, HER-2 score 1þ (Hercep Test II, TM 100). But, HER-2 gene was amplified by fluorescence in situ hybridization. four (13%), II in eight (26%), IIIa in seven (23%), IIIb in four (13%) and IV in eight (26%). The mean number of the metastasized organs identified at autopsy per patient was 5.3 [standard deviation (SD), 2.5], and mean survival after the start of treatment was 33.9 months (SD, 24.7 months), ranging from 2 to 107 months. Thirty patients died before the clinical use of trastuzumab as the drug was available to only one. The most commonly seen histological type of breast cancer was scirrhous carcinoma (15 cases, 48%), followed by solid-tubular carcinoma (eight cases, 26%), papillotubular carcinoma (five cases, 16%) and others (three cases). Hematoxylin eosin (HE) staining and immunohistological staining using Hercep Test II TM (DAKO, Denmark) were performed on the primary tumors and on the lung, liver, brain and bone metastatic tumors in accordance with the standard testing procedure. HER-2 protein overexpression was scored from 0 to 3þ in accordance with the criteria for evaluation (Fig. 1). Then, HER-2 status was categorized into twogroups:overexpression(her-2score3þ) and nonoverexpression (HER-2 score 2þ, 1þ or 0). For those cases in which the HER-2 status of the primary and each metastatic foci were inconsistent, fluorescence in situ hybridization (FISH) test was conducted. Nuclear atypia and mitotic counts were scored from one to three based on the malignancy criteria specified in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol (8 10) and nuclear grades were based on the combined scores. The chi-square test was used for statistical analysis, with the significance level set at 5%. RESULTS CASE DISPOSITION The numbers of primary carcinomas of nuclear Grades 1, 2 and 3 were two (7%), eight (26%) and 21 (67%) (Table 1). The HER-2 score in the primary tumor was 0 in 15 (48%), 1þ in five (16%), 2þ in two (7%) and 3þ in nine (29%). The lung, liver, bone and brain metastases were found on autopsy in 26, 23, 13 and 12 patients, respectively. Metastases to multiple organs occurred in 25 patients. HER-2 STATUS AND NUCLEAR GRADE OF PRIMARY TUMOR The relationship between HER-2 status and nuclear grade is shown in Table 2. In 10 cases, the nuclear grade was 1 or 2 and HER-2 status was termed non-overexpression. Of 21 cases with nuclear Grade 3, the HER-2 status overexpression was found in nine cases (43%). Frequency of the combination of HER-2 status overexpression and nuclear Grade 3 was significantly higher (P ¼ ). Table 1. Histological features and HER-2 status in 31 primary breast cancers Histological type Papillo-tubular carcinoma 5 Solid-tubular carcinoma 8 Scirrhous carcinoma 15 Others 3 Nuclear grade Grade 1 2 Grade 2 8 Grade 3 21 HER-2 score in primary tumor Score 0 15 Score 1þ 5 Score 2þ 2 Score 3þ 9 Metastatic sites Lung 26 Liver 23 Brain 12 Bone 13
3 Jpn J Clin Oncol 2008;38(11) 745 Table 2. Relationship between HER-2 status and nuclear grade (31 cases) HER-2 status FREQUENCY OF METASTASIS BY ORGAN Nuclear grade Metastasis was found in the lung, liver, bone and brain in 26 (84%), 23 (74%), 13 (42%) and 12 cases (39%), respectively. It was also seen in the adrenal gland, heart, kidney, ovaries, peritoneum, spleen, skin (local recurrence to skin was excluded from the number) and thyroid in 12, 11, 7, 5, 4, 4, 4 and 4 patients, respectively. HER-2 STATUS IN METASTATIC TUMORS Grade 1,2 Grade 3 Non-overexpression Overexpression 0 9 Frequency of the combination of HER-2 status and nuclear Grade 3 was significantly higher (P ¼ ). The correlations of HER-2 expression status of the primary tumors with metastatic foci of the lung, liver, brain and bone are given in Table 3. In those 31 patients, the HER-2 status in the primary tumors was consistent with the metastatic foci of the lung, liver, brain and bone in 96% (25 of 26), 91% (21 of 23), 100% (12 of 12) and 85% (11 of 13) patients, respectively. HER-2 overexpression was detected in seven of 26 (27%) lung metastatic tumors, seven of 23 (30%) liver metastatic tumors, only one of 12 (8%) brain metastatic tumors and only one of 13 (8%) bone metastatic tumors. The frequency of HER-2 overexpression in the cases with brain or bone metastasis was significantly lower than that in the cases with the lung or liver metastases (Table 3). With regard to the nine patients with HER-2 score 3þ primary tumors, the HER-2 status in the primary tumors was consistent with the metastatic foci of the lung, liver, brain and bone in 87% (seven of eight), 78% (seven of nine), 100% (only one) and 33% (one of three) patients, respectively. In eight of the nine patients, a score of HER-2 3þ was detected not only in the primary tumors but also in any metastatic foci (Table 4). And there were no pairs of primary and metastatic tumors that showed HER-2 overexpression only in the metastatic tumors. For the four patients showing discordance in the HER-2 status between the primary tumors and metastatic foci, HER-2geneamplificationinthesixmetastasisfociwas examined using FISH. Immunohistochemically, HER-2 score in these foci was 0 or 1þ in five and 2þ in one. Of these foci, HER-2 gene amplification was detected by FISH in brain metastatic foci in one patient (Fig. 1). Table 3. Comparison of HER-2 status between primary and metastatic tumors in 31 patients with breast cancers HER-2 score in primary tumor DISCUSSION HER-2 score in lung metastasis Total Number of cases (%) 3þ 0, 1þ, or2þ Lung metastasis 3þ 8 7 (87) 1 (13) 0, 1þ, or2þ 18 0 (0) 18 (100) Total 26 7 (27) 19 (73) Liver metastasis 3þ 9 7 (78) 2 (22) 0, 1þ, or2þ 14 0 (0) 14 (100) Total 23 7 (30) 16 (70) Brain metastasis 3þ 1 1 (100) 0 (0) 0, 1þ, or2þ 11 0 (0) 11 (100) Total 12 1 (8) 11 (92) Bone metastasis 3þ 3 1 (33) 2 (67) 0, 1þ, or2þ 10 0 (0) 10 (100) Total 13 1 (8) 12 (92) Since it was first reported in the Lancet (11), hormone therapy has been used for the treatment of breast cancer for over 100 years. A wide range of chemotherapies for breast cancer has now become available because numerous anti-cancer drugs, such as the taxanes, have been developed. Table 4. HER-2 score in primary and metastatic foci with HER-2 3þ primary tumors Primary Lung Liver Brain Bone 3þ none 1þ!FISH (2) 1þ!FISH (þ) 0!FISH (2) 3þ 3þ 0!FISH (2) None None 3þ 2þ!FISH (2) 3þ None None 3þ 3þ 3þ None 0!FISH (2) 3þ 3þ 3þ None 3þ FISH, fluorescence in situ hybridization. For the four patients showing discordance in the HER-2 status between the primary tumors and six metastatic foci, HER-2 gene amplification was examined by FISH. Five cases showed discrepancy in the HER-2 status, and amplification was detected in the primary tumors and metastatic foci of the brain.
4 746 HER-2 overexpression metastatic breast cancer HER-2/neu oncogene was first identified in 1984 (12) and HER-2 protein overexpression was found to be correlated with poor breast cancer prognosis in 1987 (13). Since then, HER-2/neu oncogene has received much attention. Clinical use of trastuzumab was started in the USA in September 1998 (National Health Insurance listing of trastuzumab in Japan started in June 2001). Thus, treatment for HER-2 positive breast cancer has dramatically advanced in the past 10 years. Since the publication of a report by Bloom and Richardson (1), the relationship between a higher histological grade that is almost equivalent to nuclear grade of breast cancer and a poorer prognosis has been widely recognized. The proportion of breast cancer with nuclear Grade 3 is said to be 25 67%, in general (14). As the patients of the current study were those subjected to autopsy, as high as 68% of those examined showed nuclear Grade 3. None of the cases with nuclear Grade 1 or 2hadHER-2score3þ, whereas 43% of those with nuclear Grade 3 had HER-2 score 3þ. Of 31 primary tumors, all nine with HER-2 score 3þ showed nuclear Grade 3. These findings suggest that patients with a potentially poor prognosis may be identified based on the combination of nuclear grade and HER-2 score. Nuclear grade was adopted as one of the breast cancer risk categories at the 9th St Gallen Expert Consensus Meeting in 2005 (2), and HER-2/neu was also newly added. This may be attributed to the worldwide recognition of the importance of an HER-2 score as a prognostic factor. As trastuzumab specifically binds to HER-2 protein, a receptor with tyrosine kinase activity that penetrates the cellular membrane, its therapeutic efficacy is largely affected by the overexpression level of HER-2 protein, which is generally seen in 10 30% of primary breast cancers (13,15). The frequency of HER-2 score 3þ in primary tumors in the current study was comparable to 29%. The frequency of HER-2 score 3þ in metastatic tumors was found in 27% in lung metastases and 30% in liver metastases. The HER-2 protein overexpression level is said to be consistent between the primary and metastatic tumors (3,4). In the current study, a high degree of agreement was seen between the HER-2 status of the primary foci and that of each of the metastatic foci of the lung, liver, brain and bone (85 100%). Among them, the frequency of HER-2 protein overexpression was highly consistent between the primary and metastatic tumors, as seen in seven of eight cases with lung metastases (88%), seven of nine with liver metastases (78%) and one brain metastasis (100%). However, the frequency of HER-2 overexpression was as low as 33% in bone metastases. In view of these findings, for those cases with the lung, liver or brain metastasis and HER-2 overexpression, it appears appropriate to make a judgment on the use of trastuzumab based on the HER-2 status of the primary foci in treating these metastatic foci. Although brain metastasis of breast cancer is generally seen in 18 30% of autopsied cases (16,17), the frequency in living patients is relatively low (14 20%) (18,19). However, an increase in brain metastases in patients with HER-2 positive recurrent breast cancer has recently been noted due to prolonged survival associated with the wide use of trastuzumab. Reported incidences of brain metastases are as high as 25 35% (20) and HER-2 positive breast cancer is likely to metastasize to the brain at high frequency (21). In the current study on 31 autopsied cases, 11 of 21 (52%) patients with HER-2 non-overexpression of primary tumors had brain metastases, whereas only one of nine cases (11%) with HER-2 overexpression did. Among the 12 cases with brain metastasis, the primary foci of 11 were HER-2 negative, which suggested that those cells that are characterized by non-overexpression of HER-2 are more likely to cause such metastasis. In conclusion, even in the far-advanced stages of autopsy, HER-2 status of the primary tumors appeared to be maintained, especially in the foci of the lung, liver and brain metastases. Because there was a high degree of agreement in HER-2 status between the primary tumors and the metastatic foci of the lung, liver and brain, it is considered to be reasonable to treat patients with such metastatic foci based on the HER-2 status of the primary tumors. Acknowledgements The authors express their gratitude to Ms Michiko Kasai, Ms Naoko Ikeda and the staff of the Department of Pathology, The Jikei University School of Medicine who participated in the preparation of the specimens. Conflict of interest statement None declared. References 1. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11: Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel Members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer Ann Oncol 2005; 16: Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, et al. c-erbb -2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73: Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93: Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000;30: Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552 6.
5 Jpn J Clin Oncol 2008;38(11) Niehans GA, Singleton TP, Dykoski D, Kiang DT. Stability of HER-2/ neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85: Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T, for the NSAS-BC pathology section. Monitoring of interobserver agreement in nuclear atypia scoring of node-negative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Protocol. Jpn J Clin Oncol 1999;29: Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T, and the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. Jpn J Clin Oncol 1999;29: Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Yamashiro K, Oyama T, et al. Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Protocol. Jpn J Cancer Res 2000;91: Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2: Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The new oncogene: An erb-b-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312: Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2 /neu oncogene. Science 1987;235: Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19: Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, et al. Similarity of protein encoded by the human c-erb-b-2 gene to receptor. Nature 1986;319: Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastases from breast carcinoma: autopsy study. Cancer 1983; 52: Lee Y-TN. Breast carcinoma. Pattern of recurrence and metastasis after mastectomy. Am J Clin Oncol 1984;7: Boogerd W, Voss VW, Hart AAM, Baris G, Grain G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 1993;15: Flowers A, Levin VA. Management of brain metastases from breast carcinoma. Oncology 1993;7: Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. JClin Oncol 2004;22: Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:
Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationKeywords Breast cancer Brain metastasis Lapatinib Capecitabine. Introduction
Int Canc Conf J (2013) 2:9 13 DOI 10.1007/s13691-012-0054-x CASE REPORT HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationConsiderable advances in the therapy of breast cancer
HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System Kelly C. Lear-Kaul, MD; Hye-Ryoung Yoon, MD; Bette K. Kleinschmidt-DeMasters, MD; Loris McGavran, PhD; Meenakshi Singh, MD Context.
More informationClinicopathologic factor and Lymphovascular Invasion in Breast cancer
ORIGINAL A R T I C L E Clinicopathologic factor and Lymphovascular Invasion in Breast cancer Ja Seong Bae, Byung Joo Song, Mi la Kim, Seok Hyo Chang 1, Han Seong Kim 2, Woo Chan Park, Jeong Soo Kim, Sang
More informationTITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.
AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School
More informationOriginal Article. Spontaneous Healing of Breast Cancer
Breast Cancer Vol. 12 No. 2 April 2005 Original Article Rie Horii 1, 3, Futoshi Akiyama 1, Fujio Kasumi 2, Morio Koike 3, and Goi Sakamoto 1 1 Department of Breast Pathology, the Cancer Institute of the
More informationA Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer
Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin
More informationMedical Treatment of Early Breast Cancer
J KMA Pharmacotherapeutics Medical Treatment of Early Breast Cancer Soon beom Kang, MD Department of Obstetrics & Gynecology, Seoul National University College of Medicine E mail : ksboo308@plaza.snu.ac.kr
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationModified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast
British Journal of Cancer (2011) 105, 698 708 All rights reserved 0007 0920/11 www.bjcancer.com Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationOutcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer
DOI:10.22034/APJCP.2017.18.4.1151 Trastuzumab RESEARCH ARTICLE Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast
More informationClinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases
Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationIs adjuvant chemotherapy necessary for Luminal A-like breast cancer?
JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
More informationT he HER2/neu type 1 tyrosine kinase growth factor
710 ORIGINAL ARTICLE HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS
ISPUB.COM The Internet Journal of Pathology Volume 13 Number 1 Learning Experience In Immunohistochemical Reporting Of Breast Cancer At A Rural Tertiary Hospital In India: A Comparison In Initial And Reviewed
More informationEvaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters
Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters Mehdi Farzadnia, Naser TayyebiMeibodi, Fatemeh HomayiShandiz,
More informationThe Role of HER-2 in Breast Cancer Bone Metastasis
AD Award Number: W81XWH-04-1-0627 TITLE: The Role of HER-2 in Breast Cancer Bone Metastasis PRINCIPAL INVESTIGATOR: Dihua Yu, MD, Ph.D. CONTRACTING ORGANIZATION: REPORT DATE: July 2005 University of Texas
More informationToru Nakamura 1, Takashi Fukutomi 1, Hitoshi Tsuda 2, Sadako Akashi-Tanaka 1, Kaneyuki Matsuo 1, Chikako Shimizu 1 and Kunihisa Miyakawa 3
Jpn J Clin Oncol 2000;30(10)453 457 Changes in Findings of Mammography, Ultrasonography and Contrast-enhanced Computed Tomography of Three Histological Complete Responders with Primary Breast Cancer Before
More informationEditorial New guidelines for HER2 pathological diagnostics in gastric cancer
bs_bs_banner Pathology International 2016; 66: 57 62 doi:10.1111/pin.12390 Editorial New guidelines for HER2 pathological diagnostics in gastric cancer Ryo Wada, 1 Kenichi Hirabayashi, 2 Nobuyuki Ohike
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationWomen with axillary lymph node-negative breast carcinoma have
2516 A Combination of HER-2 Status and the St. Gallen Classification Provides Useful Information on Prognosis in Lymph Node-Negative Breast Carcinoma Jong-Mu Sun, M.D. 1 Wonshik Han, M.D. 2 Seock-Ah Im,
More informationRESEARCH ARTICLE. Fatih Selcukbiricik 1 *, Sibel Erdamar 2, Evin Buyukunal 3, Suheyla Serrdengecti 3, Fuat Demirelli 3. Abstract.
DOI:http://dx.doi.org/10.731/APJCP.201.15.2.10607 RESEARCH ARTICLE Is Her-2 Status in the Primary Tumor Correlated with Matched Lymph Node Metastases in Patients with Gastric Cancer Undergoing Curative
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationChinese Bulletin of Life Sciences. Over-expression of HER-2/neu and targeted therapy. CHEN Yu-ping
22 1 2010 1 Chinese Bulletin of Life Sciences Vol. 22, No. 1 Jan., 2010 1004-0374(2010)01-0069-05 HER-2/neu 100048 HER-2/neu HER- 2/neu 20%~30% P185HER2 P185HER2 (Herceptin) HER2/neu HER-2/neu P185HER2
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 211 March; 14(1): 33-38 The 7-Gene Prognostic Signature for Korean Breast Cancer Patients Kuk Young Na, Ku Sang Kim, Jeong Eon Lee 1, Hee Jeong
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationBreast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens
Breast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens M. Shahid Siddiqui,Naila Kayani,Sara Sulaiman,Akbar S. Hussainy,Sajid H. Shah,Suhail Muzaffar ( Faculty of Health Sciences,
More informationORIGINAL ARTICLE BREAST ONCOLOGY. Ann Surg Oncol (2010) 17: DOI /s x
Ann Surg Oncol (2010) 17:2690 2695 DOI 10.1245/s10434-010-1052-x ORIGINAL ARTICLE BREAST ONCOLOGY Discordance of Intraoperative Frozen Section Analysis with Definitive Histology of Sentinel Lymph Nodes
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationAlterations in Hormonal Receptor Expression and HER2 Status between Primary Breast Tumors and Paired Nodal Metastases: Discordance Rates and Prognosis
RESEARCH ARTICLE Alterations in Hormonal Receptor Expression and HER2 Status between Primary Breast Tumors and Paired Nodal Metastases: Discordance Rates and Prognosis Jin-Ling Ba, Cai-Gang Liu, Feng Jin*
More informationThe role of p95her2 in trastuzumab resistance in breast cancer
JBUON 2016; 21(2): 382-389 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE The role of p95her2 in trastuzumab resistance in breast cancer Nuket
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationPrognostic Significance of HER-2/neu Overexpression in Stage I Adenocarcinoma of Lung
Prognostic Significance of HER-2/neu Overexpression in Stage I Adenocarcinoma of Lung Chih-Cheng Hsieh, MD, Kuan-Chih Chow, PhD, Huei-Jyh Fahn, MD, Chun-Ming Tsai, MD, Wing-Yin Li, MD, Min-Hsiung Huang,
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationExpression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer
MOLECULAR AND CLINICAL ONCOLOGY 2: 751-755 Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer RYOSUKE SHIBATA 1,
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationStudy of Fine Needle Aspiration Cytology of Breast Lump: Correlation of Cytologically Malignant Cases with Their Histological Findings
Study of Fine Needle Aspiration Cytology of Breast Lump: Correlation of Cytologically Malignant Cases with Their Histological Findings Touhid Uddin Rupom 1, Tamanna Choudhury 2, Sultana Gulshana Banu 3
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationReviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:
Reviewer's report Title: Validation of HER2 testing with core needle biopsy specimens from primary breast cancers in terms of interobserver reproducibility and concordance with surgically resected specimens
More informationHER2/neu Evaluation of Breast Cancer in 2019
HER2/neu Evaluation of Breast Cancer in 2019 A.A. Sahin, M.D. Professor of Pathology and Translation Molecular Pathology Section Chief of Breast Pathology ERBB2 (HER2) Background 185-kDa membrane protein
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationCase Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland
Pathology International 2008; 58: 322 326 doi:10.1111/j.1440-1827.2008.02231.x Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland Hidetaka Yamamoto, 1 Hideoki Uryu,
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationCHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD ( ) - A RETROSPECTIVE ANALYSIS
Archive of Oncology 2000;8(Suppl 1):7. SESSION 1 CHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD (1995-2000) - A RETROSPECTIVE ANALYSIS 7 Archive of Oncology 2000;8(Suppl 1):8. 8 Extended
More informationSerum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer
Original Article DOI: 10.21276/awch.1782 Serum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer Mohd Rafey 1, Kafil Akhtar 1 *, Atia Z Rab 2 and Shahid A Siddiqui
More informationCPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer
CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer The Harvard community has made this article openly available. Please share how this
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationPost Neoadjuvant therapy: issues in interpretation
Post Neoadjuvant therapy: issues in interpretation Disclosure: Overview D Prognostic features in assessment of post treatment specimens: Tumor size Cellularity Grade Receptors LN Neoadjuvant chemotherapy:
More informationRadiotherapy and Oncology
Radiotherapy and Oncology 9 (29) 74 79 Contents lists available at ScienceDirect Radiotherapy and Oncology journal homepage: www.thegreenjournal.com Postmastectomy irradiation High local recurrence risk
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationThe Clinical Significance of. Triple-negative Phenotype on. Cancer Patients
The Clinical Significance of Triple-negative Phenotype on Prognosis of Young Age( 35) Breast Cancer Patients IM-KYUNG KIM Department of Medicine The Graduate School, Yonsei University The Clinical Significance
More informationc-erbb-2 overexpression and histologlical type of in situ and invasive breast carcinoma
16 J Clin Pathol 1992;45:16-20 Department of Histopathology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD J E Somerville L A Clarke J D Biggart Correspondence to: Dr J Somerville Accepted for publication
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationPrediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
658 & 2013 USCAP, Inc All rights reserved 0893-3952/13 $32.00 OPEN Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis Molly E Klein
More informationProlonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications
Japanese Journal of Clinical Oncology, 2015, 45(8) 713 718 doi: 10.1093/jjco/hyv067 Advance Access Publication Date: 15 May 2015 Original Article Original Article Prolonged survival after diagnosis of
More informationEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
ONCOLOGY REPORTS 21: 413-417, 2009 413 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer HIROKO NOGI 1, TADASHI KOBAYASHI 2, MASAFUMI SUZUKI 3, ISAO TABEI
More informationHER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
Original article Annals of Oncology 13: 1398 1403, 2002 DOI: 10.1093/annonc/mdf217 HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationPrediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography
Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Eyad Fawzi AlSaeed 1 and Mutahir A. Tunio 2* 1 Consultant Radiation Oncology, Chairman
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationHER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD
HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD Carcinoma of the stomach is the fourth most common cancer and second most frequent cause of cancer-related mortality
More informationAssessment of Microvessel Density (Angiogenesis) And Its Correlation with Tumor Grade
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 3 Ver. XI (March. 2017), PP 15-19 www.iosrjournals.org Assessment of Microvessel Density (Angiogenesis)
More informationGood Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers q
European Journal of Cancer 40 (2004) 1837 1841 European Journal of Cancer www.ejconline.com Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationTumour markers in breast carcinoma correlate with grade rather than with invasiveness
doi: 10.1054/ bjoc.2001.1995, available online at http://www.idealibrary.com on http://www.bjcancer.com Tumour markers in breast carcinoma correlate with grade rather than with invasiveness F Wärnberg
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationUnderstanding Tumor Markers for Breast and Colorectal Cancers. A Patient s Guide. Recommendations of the American Society of Clinical Oncology
Cover Layout 1 A Patient s Guide Understanding Tumor Markers for Breast and Colorectal Cancers Recommendations of the American Society of Clinical Oncology ... Cover Layout 2 A Patient s Guide Understanding
More informationA COMPARISON OF THE EFFECT OF COMMERCIAL
African Journal of Cellular Pathology 6:1-5 (016) The Official Journal of the Society for Cellular Pathology Scientists of Nigeria www.ajcpath.com A COMPARISON OF THE EFFECT OF COMMERCIAL ph BUFFERS ON
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationRare types of breast carcinoma
Open Med. 2015; 10: 92-96 Research Article Open Access Daiva Gudaviciene*, Laura Steponaviciene, Raimundas Meskauskas, Giedre Smailyte, Eduardas Aleknavicius Rare types of breast Abstract: Breast cancer
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationImportance of confirming HER2 overexpression of recurrence lesion in breast cancer patients
Breast Cancer (2013) 20:336 341 DOI 10.1007/s12282-012-0341-6 ORIGINAL ARTICLE Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Rikiya Nakamura Naohito Yamamoto
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationMetastatic mechanism of spermatic cord tumor from stomach cancer
Int Canc Conf J (2013) 2:191 195 DOI 10.1007/s13691-013-0-9 CANCER BOARD CONFERENCE Metastatic mechanism of spermatic cord tumor from stomach cancer Masahiro Seike Yoshikazu Kanazawa Ryuji Ohashi Tadashi
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationAssessment of Her-2/neu Overexpression in Primary Breast Cancers and Their Metastatic Lesions: An Immunohistochemical Study
Annals o f Clinical & Laboratory Science, vol. 30, no. 3, 2000 259 Assessment of Her-2/neu Overexpression in Primary Breast Cancers and Their Metastatic Lesions: An Immunohistochemical Study Shahla Masood
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationCirculating Tumor Cells in non- Metastatic Triple Negative Breast Cancer
Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer
More informationHeather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,
More information